Trial Profile
Phase II study of VCD therapy in patients with newly diagnosed, transplantation-eligible symptomatic multiple myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Jul 2016 Status changed from recruiting to completed.
- 25 Jan 2013 New trial record